Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI1341 Single Ascending Dose Study in Healthy Volunteers
NCT03272165Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI1341 in Parkinson's disease (PD) (7 arms), sponsored by AstraZeneca. Primary endpoints: Treatment Emergent Adverse Events, Abnormal Vital Signs, Physical and Neurological Examinations and 9 more. Started Oct 2017; status: completed.
02
Drugs
MEDI1341
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03272165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272165.